Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KP-2350
- Development stage
- Unknown
- Lead developer
- KinoPharma
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
KP-2350 is an investigational small molecule antiviral drug candidate developed by KinoPharma for the treatment of Epidemic Keratoconjunctivitis (EKC). The compound is designed to inhibit the replication of multiple adenovirus serotypes that are the primary causative agents of severe EKC, specifically targeting types 8, 19, 37, 53, 54, and 56. By providing direct antiviral activity at the site of infection through topical ophthalmic administration, KP-2350 aims to reduce the duration and severity of clinical symptoms and prevent long-term corneal complications such as subepithelial infiltrates. As of the latest pipeline updates, KP-2350 is in Phase 1 clinical development.
- Other names
- EKC TreatmentEpidemic Keratoconjunctivitis Treatment
02
Targets
HAdV-37 (Human adenovirus 37)HAdV-D54 (Human adenovirus type 54)HAdV-56 (Human adenovirus 56)HAdV-8 (Human adenovirus type 8)
Beyond the preview
Go deeper on KP-2350.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KP-2350.